PureTech Health Past Earnings Performance

Past criteria checks 0/6

PureTech Health's earnings have been declining at an average annual rate of -59.6%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 14.4% per year.

Key information

-59.6%

Earnings growth rate

-59.9%

EPS growth rate

Biotechs Industry Growth-14.6%
Revenue growth rate-14.4%
Return on equity-29.4%
Net Margin-17,620.9%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How PureTech Health makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

DB:0VQ0 Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 240-82550
31 Mar 242-74540
31 Dec 233-66530
30 Sep 238-56580
30 Jun 2312-47640
31 Mar 2314-49620
31 Dec 2216-50610
30 Sep 2217-3258-55
30 Jun 2219-1455110
31 Mar 2218-3756110
31 Dec 2117-61570
30 Sep 2114-12755137
30 Jun 2111-193540
31 Mar 2111-94520
31 Dec 201264982
30 Sep 2012239500
30 Jun 2012472520
31 Mar 2011446550
31 Dec 1910421590
30 Sep 1915229560
30 Jun 192037530
31 Mar 1920-3500
31 Dec 1821-44470
30 Sep 18149480
30 Jun 18761480
31 Mar 18544470
31 Dec 17326460
30 Sep 174-1743-8
30 Jun 175-6140-15
31 Mar 175-5539-8
31 Dec 164-49370
30 Sep 163-543914
30 Jun 161-594028
31 Mar 166-493823
31 Dec 1512-393619
30 Sep 1512-373115
30 Jun 1512-352610
31 Mar 157-38208
31 Dec 142-42145
31 Dec 139-574

Quality Earnings: 0VQ0 is currently unprofitable.

Growing Profit Margin: 0VQ0 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 0VQ0 is unprofitable, and losses have increased over the past 5 years at a rate of 59.6% per year.

Accelerating Growth: Unable to compare 0VQ0's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 0VQ0 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).


Return on Equity

High ROE: 0VQ0 has a negative Return on Equity (-29.38%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/29 13:48
End of Day Share Price 2024/12/27 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

PureTech Health plc is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter WelfordJefferies LLC
Thomas SmithLeerink Partners LLC
Faisal KhurshidLeerink Partners LLC